Rising Biosciences (Rising Biosciences) Gross-Profit-to-Asset % : 0.00% (As of . 20)

View and export this data going back to . Start your Free Trial

What is Rising Biosciences Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Rising Biosciences's annualized Gross Profit for the quarter that ended in . 20 was $ Mil. Rising Biosciences's average Total Assets over the quarter that ended in . 20 was $ 0 Mil. Therefore, Rising Biosciences's annualized Gross-Profit-to-Asset % for the quarter that ended in . 20 was Not Available.

Rising Biosciences Gross-Profit-to-Asset % Historical Data

The historical data trend for Rising Biosciences's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences Gross-Profit-to-Asset % Chart

Rising Biosciences Annual Data

Trend

Gross-Profit-to-Asset %

Rising Biosciences Quarterly Data

Gross-Profit-to-Asset %

Competitive Comparison of Rising Biosciences's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Rising Biosciences's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rising Biosciences's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rising Biosciences's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Rising Biosciences's Gross-Profit-to-Asset % falls into.

Rising Biosciences Gross-Profit-to-Asset % Calculation

Rising Biosciences's annualized Gross-Profit-to-Asset % for the fiscal year that ended in . 20 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: . 20 )	/	( (Total Assets (A: . 20 )	+	Total Assets (A: . 20 ))	/ count )
	=		/	( (	+	)	/ )
	=		/
	=	%

Rising Biosciences's annualized Gross-Profit-to-Asset % for the quarter that ended in . 20 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: . 20 )	/	( (Total Assets (Q: . 20 )	+	Total Assets (Q: . 20 ))	/ count )
	=		/	( (	+	)	/ )
	=		/
	=	%

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (. 20) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Rising Biosciences Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Rising Biosciences's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Rising Biosciences (Rising Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Gross-Profit-to-Asset %

Traded in Other Exchanges

N/A

Address

1180 Cleveland Road, Sandusky, OH, USA, 44870

Website

http://www.risingbiosciences.com

Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.